2425 55th Street, Suite 210 Boulder, CO 80301 303-420-4420

Study: The ability of granulocyte-macrophage colony stimulating factor (GM-CSF) to reverse Alzheimer’s disease and cognitive impairment in a mouse model of Alzheimer’s Disease

9 News in Denver, Colorado aired a series of reports highlighting recent progress in the fight against Alzheimer’s Disease.  One of the reports focused on studies led by Huntington Potter, Ph.D., Professor of Neurology and Director of Alzheimer’s Disease Research in the Department of Neurology and the Linda Crnic Center for Down Syndrome at the University of Colorado, Denver, demonstrating the ability of GM-CSF to reverse Alzheimer’s Disease and cognitive impairment in a mouse model of Alzheimer’s Disease.

Dr. Potter currently is conducting a clinical trial with a recombinant human GM-CSF product in patients with Alzheimer’s Disease.  The 9 News series also reported on Dr. Potter’s research into potential shared mechanisms underlying the related brain pathologies present in Alzheimer’s Disease patients and Down Syndrome patients.  BBT-007, Bolder BioTechnology’s long-acting GM-CSF analog, could prove to be an attractive alternative to GM-CSF for treating Alzheimer’s Disease due to BBT-007’s less frequent dosing requirements and potentially improved safety and efficacy.

9 News’ March 2, 2017 video report “New Hope for Alzheimer’s” is available for viewing at http://www.globaldownsyndrome.org/9-news-leukine.